Clinical Trials Logo

Malignant Mesothelioma clinical trials

View clinical trials related to Malignant Mesothelioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06256055 Recruiting - Colorectal Cancer Clinical Trials

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Start date: March 5, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.

NCT ID: NCT06057935 Recruiting - Mesothelioma Clinical Trials

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Start date: September 21, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

NCT ID: NCT03852823 Recruiting - Lymphoma Clinical Trials

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Start date: May 23, 2019
Phase: Phase 1
Study type: Interventional

This study is an open, multi-dose, dose escalation and cohort expansion, phase Ⅰ study to investigate the safety, tolerability, efficiency, pharmacokinetics, immunogenicity of SG001 in subjects with advanced tumours.

NCT ID: NCT03007030 Recruiting - Clinical trials for Malignant Mesothelioma

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

Start date: April 5, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02580747 Recruiting - Pancreatic Cancer Clinical Trials

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Start date: October 2015
Phase: Phase 1
Study type: Interventional

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.

NCT ID: NCT01655888 Recruiting - Clinical trials for Malignant Mesothelioma

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

Start date: July 2012
Phase: Phase 2
Study type: Interventional

RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of tremelimumab in malignant mesothelioma (MM) patients. PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks until confirmed disease progression.

NCT ID: NCT00899613 Recruiting - Metastatic Cancer Clinical Trials

Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia

Start date: April 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at mesothelin and osteopontin as diagnostic markers in patients with mesothelioma or atypical hyperplasia.